Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial

Summary

This safety pilot study evaluates the effect of hydroxychloroquine on preventing recurrent cardiovascular events among myocardial infarction patients. Half of the participants will receive hydroxychloroquine, whereas the other half will receive placebo during six months.

Timeline

Start

2016-02-01

Primary completion

2019-12-31

Completion

2019-12-31

Publications

• Background Hartman O, Kovanen PT, Lehtonen J, Eklund KK, Sinisalo J. Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. Eur Heart J Cardiovasc Pharmacother. 2017 Apr 1;3(2):92-97. doi: 10.1093/ehjcvp/pvw035.
• Simonen P, Ulander L, Eklund KK, Niemi M, Backman JT, Gylling H, Sinisalo J; OXI pilot trial. The effect of hydroxychloroquine on cholesterol synthesis depends on the profile of cholesterol metabolism. A controlled clinical study. Atheroscler Plus. 2024 Mar 1;55:93-97. doi: 10.1016/j.athplu.2024.02.002. eCollection 2024 Mar.
• Ulander L, Simonen P, Tolppanen H, Hartman O, Rissanen TT, Eklund KK, Kalaoja M, Kurkela M, Neuvonen M, Niemi M, Backman JT, Gylling H, Sinisalo J; OXI pilot trial. The effect of hydroxychloroquine on cholesterol metabolism in statin treated patients after myocardial infarction. Atheroscler Plus. 2023 Jun 26;53:26-32. doi: 10.1016/j.athplu.2023.06.003. eCollection 2023 Sep.

Drugs

Indications